Holding(s) in Company

Plethora Solutions Holdings PLC

("Plethora" or "the Company")

Holding in Company

Plethora Solutions Holdings PLC (AIM: PLE), the UK-based speciality pharmaceutical company, has been notified today that following recent sales, Helium Special Situations Fund now holds 10,400,000 ordinary shares in Plethora, representing approximately 4.98% of the issued ordinary share capital.

Plethora Solutions Holdings PLC

Ronal Openshaw, Chief Executive Officer

Tel: + 44 (0) 20 3077 5400

Daniel Stewart & Company Plc

(Nominated Adviser & Joint Broker)

David Hart/James Felix

Tel: + 44 (0) 20 7776 6550

Hybridan LLP

(Joint Broker)

Claire Louise Noyce/Deepak Reddy

Tel: + 44 (0) 20 7947 4350

Britton Financial PR

Tim Blackston

(Tel: + 44 (0) 20 7241 9786

About Plethora:

Plethora is focussed on the development and marketing of products for the treatment of urological disorders.

Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk and www.theurologyco.com

Plethora is focussed on: (i) seeking to launchPSD502 for the treatment of premature ejaculation; and (ii) driving the development of its speciality sales and marketing business, The Urology Co.

About PSD502 & Premature Ejaculation:

PSD502 is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture. The product has completed all clinical testing and has been submitted for approval in Europe with the EMA. The Company anticipates launch in late 2013 or early 2014.

Premature ejaculation is possibly the most common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20 - 30% in men of all ages. There is currently no globally approved and effective pharmaceutical treatment for this condition.

In the absence of any widely approved pharmaceutical therapy with good patient acceptance, the premature ejaculation market offers significant potential for development and growth. An effective drug therapy for premature ejaculation may have a comparable commercial potential to the erectile dysfunction drugs.

About The Urology Co:

Plethora's subsidiary, The Urology Co, established in 2009, markets and distributes a range of pharmaceutical products, pharmaceutical specials, medical devices and nutritional supplements for the treatment of urology, sexual health, gynaecology and reproductive health conditions. Its products fall into two categories (i) Professional - where a physician, nurse or other healthcare professional makes a prescribing decision and include Gepan® instil, Striant® SR, Urolieve®, Hyalofemme® and Dianatal®; and (ii) Consumer - where the consumer/patient makes a buying decision and include Hyalofemme®, Multi-Gyn®, Multi-Mam® and hI-Cran®.